<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28193">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02739698</url>
  </required_header>
  <id_info>
    <org_study_id>PI 0678-10</org_study_id>
    <nct_id>NCT02739698</nct_id>
  </id_info>
  <brief_title>Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus Normothermia</brief_title>
  <official_title>Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus Normothermia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimónides Biomedical Research Institute of Córdoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimónides Biomedical Research Institute of Córdoba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized controlled single-blind clinical trial was performed, in 32 patients diagnosed
      with peritoneal carcinomatosis from epithelial ovarian cancer, who underwent radical
      surgery-peritonectomy, achieving an optimal R0-R1 cytoreduction (microscopic tumor residues
      (R0) or macroscopic tumor residues &lt; 1cm (R1)) followed by hyperthermia against normothermia
      intraperitoneal intraoperative chemotherapy with paclitaxel
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2012</start_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological response change (Miller &amp; Payne System )</measure>
    <time_frame>60 minutes</time_frame>
    <description>Histopathology scoring system to assess response, previous and post intraperitoneal intraoperative chemotherapy. Compare cancer cellularity of the biopsy (before treatment) with the other biopsy (after treatment).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Peritoneal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>normothermic (36-37ºC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1, n=16(normothermic): Intraperitoneal administration of 60 mg/m2 paclitaxel per 2 liters of 1,5% dextrose in room temperature (36-37ºC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hyperthermic (42-43ºC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2, n=16 (hyperthermic): Intraperitoneal administration of 60 mg/m2 paclitaxel per 2 liters of 1,5% dextrose in continuous hyperthermic perfusion (42-43ºC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>normothermic (36-37ºC)</arm_group_label>
    <arm_group_label>hyperthermic (42-43ºC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical surgery-peritonectomy</intervention_name>
    <arm_group_label>normothermic (36-37ºC)</arm_group_label>
    <arm_group_label>hyperthermic (42-43ºC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age ranged between 18 and 75 years old;

          2. histopathologic confirmation of peritoneal carcinomatosis from epithelial ovarian
             cancer (stage IIIc- FIGO (International Federation of Gynecology and Obstetrics));

          3. Karnofsky index &gt; 70 or performance status ≤2;

          4. informed consent form filled out correctly.

        Exclusion Criteria:

          1. unfulfillment of inclusion criteria;

          2. extraabdominal metastasis or stage IV FIGO (liver, lung, bone, etc);

          3. concomitance of another malignant neoplasm;

          4. renal, hepatic or cardiovascular dysfunction;

          5. intolerance during the treatment; - (6) refusal to participate in the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 11, 2016</lastchanged_date>
  <firstreceived_date>April 4, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maimónides Biomedical Research Institute of Córdoba</investigator_affiliation>
    <investigator_full_name>Sebastián Rufián</investigator_full_name>
    <investigator_title>PhD, MD</investigator_title>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
